Is induction of type 2 programmed death in cancer cells from solid tumors directly related to mitochondrial mass?
1Department of Medicine, Rush Medical College, Chicago, USA.
Abstract:
Many solid cancers respond to chemo or radiotherapy with a type 2 form of programmed cell death. This requires direct participation of mitochondria with release of cytochrome c and other factors that activate the 'execution' phase of the process. It is believed that as solid cancers progress, less differentiated clones containing fewer mitochondria evolve. Consequently, the mitochondrial 'switch' that activates the type 2 process will become less effective, as the number of elements available and their mass-effect declines. The opportunity for successful therapy, considered to depend upon the ability to activate programmed cell death, therefore becomes progressively less probable.
Insights
Solid cancers treated with chemotherapy or radiotherapy rely on programmed cell death, a process dependent on mitochondria. As cancers progress, fewer mitochondria reduce treatment effectiveness.
Area of Science:
- Oncology
- Cell Biology
- Cancer Therapeutics
Background:
- Solid cancers often respond to chemotherapy and radiotherapy through type 2 programmed cell death.
- This cell death pathway necessitates the direct involvement of mitochondria, leading to the release of cytochrome c.
- Mitochondria play a crucial role in activating the execution phase of programmed cell death.
Purpose of the Study:
- To investigate the relationship between cancer progression and the efficacy of mitochondrially-mediated cell death.
- To understand how changes in mitochondrial content during cancer progression impact therapeutic responses.
Main Methods:
- The study is based on established biological principles and existing research on cancer cell death pathways.
- It involves theoretical analysis of mitochondrial dynamics in evolving cancer clones.
- No new experimental data was generated; it is a conceptual review.
Main Results:
- Solid cancers that progress tend to evolve less differentiated clones.
- These less differentiated clones possess fewer mitochondria compared to earlier stages.
- The reduced mitochondrial mass diminishes the effectiveness of the programmed cell death 'switch'.
Conclusions:
- The declining mitochondrial content in advanced solid cancers compromises the activation of type 2 programmed cell death.
- Consequently, the probability of successful chemo- or radiotherapy diminishes as the cancer progresses.
- Therapeutic strategies may need to consider or overcome this mitochondrial limitation in later-stage cancers.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
01:30Apoptosis
01:31The Intrinsic Apoptotic Pathway
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...